Literature DB >> 31697281

UPDATE ON THE USE OF QUADRIVALENT CONJUGATE MENINGOCOCCAL VACCINES: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

This Statement Was Prepared By Dr B Warshawsky.   

Abstract

Year:  2013        PMID： 31697281      PMCID： PMC6802440          DOI： 10.14745/ccdr.v39i00a01

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN： 1188-4169


× No keyword cloud information.
  40 in total

1.  Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.

Authors:  P Richmond; R Borrow; E Miller; S Clark; F Sadler; A Fox; N Begg; R Morris; K Cartwright
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-01-28       Impact factor: 17.586

3.  Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.

Authors:  Scott A Halperin; Anil Gupta; Robert Jeanfreau; Nicola P Klein; Keith Reisinger; Emmanuel Walter; Lisa Bedell; Christopher Gill; Peter M Dull
Journal:  Vaccine       Date:  2010-10-29       Impact factor: 3.641

4.  Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2007-11

5.  Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.

Authors:  Christopher J Gill; Roger Baxter; Alessandra Anemona; Giuseppe Ciavarro; Peter Dull
Journal:  Hum Vaccin       Date:  2010-11-01

6.  Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

Authors:  P Richmond; R Borrow; D Goldblatt; J Findlow; S Martin; R Morris; K Cartwright; E Miller
Journal:  J Infect Dis       Date:  2000-11-14       Impact factor: 5.226

Review 7.  Meningococcal polysaccharide-protein conjugate vaccines.

Authors:  Matthew D Snape; Andrew J Pollard
Journal:  Lancet Infect Dis       Date:  2005-01       Impact factor: 25.071

8.  Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults.

Authors:  Roberto Gasparini; Michele Conversano; Gianni Bona; Giovanni Gabutti; Alessandra Anemona; Peter M Dull; Francesca Ceddia
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

9.  Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.

Authors:  Ray Borrow; David Goldblatt; Adam Finn; Joanna Southern; Lindsey Ashton; Nick Andrews; Gouri Lal; Christine Riley; Rukhsana Rahim; Keith Cartwright; Geraldine Allan; Elizabeth Miller
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

10.  An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2009-04
View more
  1 in total

1.  Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada.

Authors:  Marie-Claude Breton; Liping Huang; Sonya J Snedecor; Noelle Cornelio; Fiorella Fanton-Aita
Journal:  Can J Public Health       Date:  2020-01-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.